AFA
0.35
4900%
MTL
0.001
-50%
VBS
0.17
129.7%
NVA
0.83
-42.4%
TAS
0.033
106.3%
VML
0.24
-34.2%
AAJ
0.029
81.3%
C7A
0.004
-33.3%
LMG
0.043
65.4%
MKR
0.062
-33.3%
MCM
0.215
65.4%
PKO
0.004
-33.3%
VHM
0.74
60.9%
TMX
0.004
-33.3%
WYX
0.07
59.1%
RML
0.08
-30.4%
GSS
0.365
52.1%
LRD
0.028
-30%
EVG
0.038
52%
SER
0.007
-30%
MSG
0.012
50%
HMI
0.039
-29.1%
ROG
0.006
50%
YUG
0.044
-29%
UNT
0.013
44.4%
ENT
0.005
-28.6%
ELT
0.36
41.2%
MRQ
0.005
-28.6%
ZAG
0.031
40.9%
RNX
0.005
-28.6%
EMU
0.045
40.6%
SRJ
0.016
-27.3%
WBE
0.007
40%
AVM
0.095
-26.9%
SKK
0.065
38.3%
BKT
0.019
-26.9%
CMG
0.22
37.5%
ADG
0.011
-26.7%
EDE
0.042
35.5%
IFG
0.011
-26.7%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CYP Phase 2 Trial approved

Cynata Therapeutics (ASX:CYP), a clinical-stage biotechnology company specialising in cell therapeutics, has received regulatory and ethics approval to commence its Phase 2 clinical trial at clinical centres in Turkey | ASX announcement: https://app.sharelinktechnologies.com/announcement/asx/e0fa6ac7f7a6ddf39eef8d4299365c12 #shorts